Brimonidine — $0 with Membership
Brimonidine has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.
Brimonidine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 with membership |
| Typical Retail | $89.99 |
Free with membership subject to the listed formulary limits.
About Brimonidine
Brimonidine is a prescription medication. Ask your doctor if Brimonidine is right for you.
Other strengths and forms of Brimonidine
Conditions Treated with Brimonidine
How to Check Brimonidine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Brimonidine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Glaucoma
Also listed for Primary Open-Angle Glaucoma
Other medications in Ophthalmology
About Brimonidine
Brimonidine is a vital medication used to manage conditions like glaucoma and ocular hypertension, protecting your precious vision. At TheDrugClub, we believe in making essential prescriptions affordable. Our members can access brimonidine with significant savings, often enjoying a $0 co-pay and the convenience of free home delivery, ensuring vital eye care is within reach.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Brimonidine is approved for (FDA label)
Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: July 31, 2024.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Brimonidine (FDA label)
Brimonidine Topical Gel, 0.33% is a white to light yellow opaque aqueous gel. Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base. Gel, 0.33%; Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: c899b329-cc5e-4443-8e94-451314de47c9. SPL document ID: 6d6fa6f0-e1c6-4ea1-a4fb-8ad511a95d75. Label effective date: July 31, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Brimonidine (FDA label)
The following adverse drug reactions are discussed in greater detail in other sections of the label: • Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists [ see Warnings and Precautions ( 5.4 ) ] • Local Vasomotor Adverse Reactions [ see Warnings and Precautions ( 5.5 ) ] • Hypersensitivity [ see Warnings and Precautions ( 5.6 ) ] In controlled clinical trials with brimonidine topical gel the most common adverse reactions (incidence ≥ 1%) included erythema, flushing, skin burning sensation, and contact dermatitis. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: c899b329-cc5e-4443-8e94-451314de47c9. SPL document ID: 6d6fa6f0-e1c6-4ea1-a4fb-8ad511a95d75. Label effective date: July 31, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Brimonidine (FDA label)
Brimonidine topical gel is contraindicated in patients who have experienced a hypersensitivity reaction to any component. Reactions have included angioedema, urticarial, and contact dermatitis [ see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 , 6.2 ) ]. Known hypersensitivity to any component of brimonidine topical gel ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: c899b329-cc5e-4443-8e94-451314de47c9. SPL document ID: 6d6fa6f0-e1c6-4ea1-a4fb-8ad511a95d75. Label effective date: July 31, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Brimonidine (FDA label)
• Potentiation of Vascular Insufficiency ( 5.1 ) • Severe Cardiovascular Disease ( 5.2 ) • Serious Adverse Reactions Following Ingestion of brimonidine topical gel ( 5.3 ) • Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists ( 5.4 ) • Local Vasomotor Adverse Reactions ( 5.5 ) • Hypersensitivity ( 5.6 ) 5.1 Potentiation of Vascular Insufficiency Brimonidine topical gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren’s syndrome. 5.2 Severe Cardiovascular Disease Alpha-2 adrenergic agonists can lower blood pressure. Brimonidine topical gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. 5.3 Serious Adverse Reactions Following Ingestion of Brimonidine Topical Gel Two young children of a subject in a clinical trial experienced serious adverse reactions following accidental ingestion of brimonidine topical gel.
Source: FDA prescribing information (DailyMed). Set ID: c899b329-cc5e-4443-8e94-451314de47c9. SPL document ID: 6d6fa6f0-e1c6-4ea1-a4fb-8ad511a95d75. Label effective date: July 31, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Brimonidine (FDA label)
7.1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7.2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7.3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.
Source: FDA prescribing information (DailyMed). Set ID: c899b329-cc5e-4443-8e94-451314de47c9. SPL document ID: 6d6fa6f0-e1c6-4ea1-a4fb-8ad511a95d75. Label effective date: July 31, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.